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Background: Understanding the genetic basis of diseases is key to the development of better diagnoses and
treatments. Unfortunately, only a small fraction of the existing data linking genes to phenotypes is available
through online public resources and, when available, it is scattered across multiple access tools.
Description: Neurocarta is a knowledgebase that consolidates information on genes and phenotypes across
multiple resources and allows tracking and exploring of the associations. The system enables automatic and manual
curation of evidence supporting each association, as well as user-enabled entry of their own annotations.
Phenotypes are recorded using controlled vocabularies such as the Disease Ontology to facilitate computational
inference and linking to external data sources. The gene-to-phenotype associations are filtered by stringent criteria
to focus on the annotations most likely to be relevant. Neurocarta is constantly growing and currently holds more
than 30,000 lines of evidence linking over 7,000 genes to 2,000 different phenotypes.
Conclusions: Neurocarta is a one-stop shop for researchers looking for candidate genes for any disorder of interest.
In Neurocarta, they can review the evidence linking genes to phenotypes and filter out the evidence they’re not
interested in. In addition, researchers can enter their own annotations from their experiments and analyze them in
the context of existing public annotations. Neurocarta’s in-depth annotation of neurodevelopmental disorders
makes it a unique resource for neuroscientists working on brain development.
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There is a tremendous amount of research focusing on
understanding the genetic basis of disease. Studies use a
wide range of strategies, including targeted gene ap-
proaches, genome-wide screens, and animal models. As
such studies continue to proliferate and provide insights
on specific disorders, it is important to integrate the
information in order to make the best use of the data
and increase the level of insight that can be gained from
new studies. Knowledge that crosses studies and disor-
ders can be used to perform meta-analyses, to uncover
commonalities among conditions, and to tease apart the
factors that contribute to phenotypes that make up a
disorder. However, currently, information about the gen-
etic and molecular basis of diseases is distributed among* Correspondence: paul@chibi.ubc.ca
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distribution, and reproduction in any mediuma range of specialized or generic data resources, hinder-
ing its optimal use [1]. Examples of more or less generic
databases are Online Mendelian Inheritance in Man
(OMIM) [2], the Rat Genome Database (RGD) [3], and
the Comparative Toxicogenomics Database (CTD) [4].
While these different resources overlap in their disease
coverage and data sources, they are also complementary
in that each of the curation teams making the annotations
has different criteria for inclusion and different biases.
Other databases are dedicated to specific disorders, these
include the Simons Foundation Autism Research Initiative
Gene Database (SFARI Gene) for autism [5], PDGene for
Parkinson’s disease [6], Alzgene for Alzheimer’s disease
[7], MSGene for multiple sclerosis [8], ADHDgene for
Attention Deficit Hyperactivity Disorder [9], and CADgene
for Coronary Artery Disease [10].
The resource we describe was motivated by the
establishment of a large Canadian research network
“NeuroDevNet”, with the goal of translating knowledged Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Portales-Casamar et al. BMC Genomics 2013, 14:129 Page 2 of 8
http://www.biomedcentral.com/1471-2164/14/129into improved diagnosis, prevention and treatment of
neurodevelopmental disorders [11,12]. To facilitate the
design and interpretation of genetics studies, we recognized
the need for a resource that captures existing information,
but none of the resources mentioned above was sufficiently
comprehensive. This was in part because genetic investiga-
tions of two of the disorders of interest to NeuroDevNet,
Fetal Alcohol Spectrum Disorder (FASD) and Cerebral
Palsy (CP) were not well covered by any existing database.
Neurocarta is an online resource focusing on the genetic
basis of neurodevelopmental disorders. In addition to
containing manually curated information on disorders of
interest to neurodevelopmental researcher, Neurocarta
aggregates data from multiple disease gene resources so
that the neurodevelopmental annotations can be examined
in the context of other disease annotations, providing a
better understanding of how generic the function of the
gene might be.
Construction and content
Database schema and implementation
Neurocarta was developed as an extension of Gemma
[13], a database and software system for the meta-analysis
of functional genomics data. Figure 1 shows a simplified
schematic of our data model used to capture information
linking genes and phenotypes. The “Gene” information is
retrieved automatically as part of the Gemma framework
from the NCBI Gene database [14]. Gemma currently
focuses on a set of selected species: human, mouse, rat,
zebrafish, fly, worm, and yeast. The “Phenotype” informa-
tion includes terms describing diseases, symptoms, and ab-
normal physical characteristics, drawn from three distinct
ontologies: (i) Disease Ontology [15]; (ii) Human Phenotype
Ontology [16]; and (iii) Mammalian Phenotype Ontology
[17]. The “Evidence” corresponds to annotations linking a
specific gene to a specific phenotype. This evidence can be
of several types: (i) Literature (reference from PubMed
[18]); (ii) Experimental (details about experimental design,
from a published article or not); and (iii) User comment.
Where possible, links are provided to the original source of
the evidence (e.g., public database, review article), and
can be defined as “positive” or “negative”, where “negative”Figure 1 Gene-to-phenotype association data model
in Neurocarta.means that the evidence shows that there is no association
between a gene and a phenotype. All evidence annotations
use standardized terminologies such as the Ontology for
Biomedical Investigations [19] to facilitate users’ interpret-
ation and enable computational analysis. Currently we do
not attempt to capture information on the specific genetic
variants associated with the disease as such information
is frequently not readily available in computable form,
making acquisition challenging.
Neurocarta benefits from the registration system
implemented in Gemma [13] allowing users the option
of registering and entering their own annotations. The
annotations can be set to be either public or private.
When private, the owner can decide whom to share them
with, using a group-based authorization framework.
Database content
Our database currently contains more than 30,000 lines
of evidence linking over 7,000 genes to 2,000 different
phenotypes (For detailed statistics, see http://www.chibi.
ubc.ca/Gemma/neurocartaStatistics.html). Figure 2 shows
the distribution of genes (2A) and phenotypes (2B) based
on how many distinct associations they are a part of.
Tables 1 and 2 detail the top ten genes and phenotypes,
respectively, with the most distinct associations. The associ-
ations are derived from manual annotations from the litera-
ture and automatic annotations from public databases.
Data extraction from external sources
We have defined stringent criteria for automatic inclusion
of data from external sources, with the goal of limiting the
inclusion of unreliable data or information that we deem of
limited utility to our target audience. In this section we pro-
vide details of procedures for each resource. As we are con-
tinuing to add resources to the system, information on the
inclusion criteria and import procedures is also maintained
on the Neurocarta website at http://gemma-doc.chibi.ubc.
ca/neurocarta/data-sources.
OMIM [2]: The OMIM data files (morbidmap.txt and
mim2gene.txt) are downloaded from the OMIM FTP
site. We extract unique mappings between Phenotype
MIM numbers and Gene MIM numbers from morbidmap.
txt and map the genes to their NCBI identifiers in
mim2gene.txt.
RGD [3]: The RGD Gene-Disease association files
(homo_genes_rdo, mus_genes_rdo, rattus_genes_rdo)
are downloaded from the RGD FTP site. Annotations
with the following evidence codes are ignored: ISS
(redundant across species), NAS (non-traceable author’s
statements are debatable), and IEA (electronic annotations
come from other sources, GAD for example) and we
prefer to get these annotations directly from the
source). Annotations without a PubMed reference are
ignored as well.
Figure 2 Distribution of genes (2A) and phenotypes (2B) based on their number of distinct associations. Each ontology term is
considered a distinct phenotype regardless of its position in the ontology tree. Therefore, a gene will be counted as associated with two distinct
phenotypes if different lines of evidence link it to a child term and its parent term.
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(CTD_genes_diseases.tsv) is downloaded from the CTD
website. We only consider curated annotations with Direct
Evidence set to “marker/mechanism” or “therapeutic”, and
at least one PubMed reference.
Disease-specific databases: The SFARI [5] annotation files
(autism-gene-dataset.csv, gene-score.csv) are downloaded
form the SFARI Gene website. Each PubMed reference is
imported as separate literature evidence in Neurocarta,
with the option of it being defined as “negative” whenever
specified in the annotation file. The PDGene [6], AlzGene
[7], and MSGene [8] “Top Results” are extracted from their
respective websites. All three databases assess their results
for their epidemiological credibility using two methods:
(1) The HuGENet interim criteria for the cumulative
assessment of genetic associations [20,21], and (2) Bayesian
analyses [22,23]. Only meta-analysis results with P-values
<0.00001 are considered. The “Hot gene list” from
ADHDgene [9] is extracted from their website. This list
includes all genes that have been identified in at least five
independent studies. The ALSoD [24] top 20 genes areTable 1 Top ten genes with the most associated phenotypes
Gene symbol Gene name
TNF tumor necrosis factor
PTGS2 prostaglandin-endoperoxide synthase 2
MMP9 matrix metallopeptidase 9
IL6 interleukin 6
PTEN phosphatase and tensin homolog
HLA-DRB1 major histocompatibility complex, class II, D
IL1B interleukin 1, beta
TP53 tumor protein p53
MTHFR methylenetetrahydrofolate reductase
TGFB1 transforming growth factor, beta 1identified through the credibility score analysis provided
on their website. The genes are ranked by the number of
affected patients and by the number of mutations per gene,
and the ranks are summed to determine the final rank for
each gene. For the IDGene [25] and EpiGAD [26] data-
bases, we wanted to extract more information than what
was readily accessible through respective websites. We
manually reviewed the genes listed in each database and
used that information as a seed for targeted PubMed
searches and manual curation of relevant publications.
Disease mapping from external sources to Disease
Ontology (DO) terminology
For the disorder-specific databases we use the correspond-
ing appropriate terms in DO (e.g., “autism spectrum
disorder” for SFARI and “amyotrophic lateral sclerosis”
for ALSoD). As described next, for other databases we
used a combination of automatic and semi-automatic
methods for mapping.
OMIM, RGD, and CTD: These three resources provide











Table 2 Top ten phenotypes with the most associated genes
Phenotype Term URI # of genes
prostate cancer http://purl.obolibrary.org/obo/DOID_10283 602
breast cancer http://purl.obolibrary.org/obo/DOID_1612 531
hypertension http://purl.obolibrary.org/obo/DOID_10763 439
autism spectrum disorder http://purl.obolibrary.org/obo/DOID_0060041 394
type 2 diabetes mellitus http://purl.obolibrary.org/obo/DOID_9352 389
asthma http://purl.obolibrary.org/obo/DOID_2841 389
obesity http://purl.obolibrary.org/obo/DOID_9970 363
peripheral nervous system disease http://purl.obolibrary.org/obo/DOID_574 296
ovarian cancer http://purl.obolibrary.org/obo/DOID_2394 273
Alzheimer’s disease http://purl.obolibrary.org/obo/DOID_10652 259
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Human_DO.obo ontology file, which covers about 50%
of the phenotype-gene mappings in these resources. For
the remaining that use terms lacking a DO Xref, we use
the NCBO Annotator Web service [27] followed by
manual quality control to resolve partial matches,
increasing coverage substantially. In total about 2/3 of
the phenotype-gene associations present in OMIM,
RGD, or CTD could be mapped to a DO term. This is
due to non-disease terms that are listed in OMIM but
not in DO (e.g., “Blood type”, “Ig levels”), and some
disease terms missing from DO (mostly syndromic, e.g.,
TARP syndrome, Jawad syndrome), or missed mappings.
We have notified the DO maintainers of these gaps and
expect to eventually be able to import a greater fraction
of these annotations into Neurocarta.
Manual curation of the literature
While the Neurocarta framework is generic, our curation
team is focusing on annotations relevant to our primary
research interest, neurodevelopmental disorders. In-depth
annotations have been produced on the following Disease
Ontology terms (including respective children terms):
(i) “Autism Spectrum Disorder” (ASD; DOID_0060041);
(ii) “Cerebral Palsy” (CP; DOID_1969); (iii) “Fetal Alcohol
Spectrum Disorder” (FASD; DOID_0050696); (iv) “Epilepsy”
(DOID_1826); and (v) and “Intellectual disability”
(DOID_1059). When necessary, phenotype descriptions
were complemented with more descriptive Human or
Mammalian Phenotype Ontology terms such as
“Memory impairment” (HP_0002354), “EEG abnormality”
(HP_0002353), or “decreased brain size” (MP_0000774).
Curators review the literature using PubMed searches
across all fields (that is, the default PubMed setting) using
queries such as “epilepsy” AND “genetics”. We avoid
making searches that are gene-centric, except as a second-
ary mechanism to find additional citations on a gene-
phenotype relationship identified through initial screening.
When possible, review papers are used to identify primaryresearch papers, which are then curated as “Experimental
Type Evidence”. The curators record details about the
experiment using controlled vocabularies, categorized as
(for example) “Bio Source”, “Experiment Design”, or
“Developmental Stage”. The criterion for inclusion is an
experimentally-supported statement linking the gene to
the phenotype. The exception is genome-wide studies
where the results were not yet confirmed by follow-up
experiments. The curated papers involve a wide variety
of experiments including both animal models and
human studies. For the former, if the authors describe
the animal model as a specific model for the disorder of
interest, the curators associate the gene studied in the
paper directly to the human disease. If the authors
describe an endophenotype that is related to the disease,
the gene is associated to the endophenotype only. In
some cases, review papers are used as the source of the
annotations instead of drilling down to the original
research papers. In that case, it is curated as “Literature
Type Evidence” with no details about the experiments.
To help users navigate through the evidence, we are,
when possible, associating phenotypes to genes in a
species-specific way. So, for instance, if the evidence
comes from an experiment done in rats, it will be linked
in Neurocarta to the rat gene.
Utility and discussion
User interface
Figure 3 shows the main Neurocarta user interface,
which is divided into three panels. The left panel lists all
phenotypes currently annotated in our system, displayed
as a tree of terms in the ontologies, or as a simple list.
By clicking on a checkbox next to the phenotype term,
one or more phenotypes can be selected and it affects
the display in the other two panels. The top-right panel
shows the list of genes associated with the selected
phenotype(s). If more than one phenotype are selected,
only genes that are associated with all of the phenotypes
are listed (i.e., the intersection of genes associated with
Figure 3 Neurocarta user interface.
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download the displayed gene lists. Once a gene of interest
is selected, the bottom-right panel shows the list of
evidence for all phenotype associations annotated for this
gene, each row being expandable to provide more details.
Evidence for the currently selected phenotype(s) and their
children terms are highlighted in red. Evidence for other
phenotypes associated with the gene are shown in black.
Evidence inferred from an orthologous gene, as defined in
the NCBI Homologene resource [14], are displayed in
grey. Links are provided to the original source of the
evidence when available. Users can filter the data displayed
to restrict to a specific species, or to the annotations they
have entered in Neurocarta.
Use cases
Neurocarta was originally conceived to help researchers
identify candidate genes that might be involved in their
disorder of interest, based on existing knowledge, and
put that information in the context of other phenotypes
associated with the genes. Neurocarta allows users to
extract the list of genes that have been associated to a
specific disorder, look at the detail of the evidence, and
apply further selection criteria. It can also be used to
identify relevant literature pertaining to a gene or pheno-
type of interest. By aggregating data from multiple sources,we enable a global view of each gene’s involvement in
diseases, facilitating the identification of genes specifically
involved in one disorder versus genes involved in many
disease processes. Such candidate gene lists can be used by
researchers who perform genome-wide studies, helping
them identifying the most likely candidates in their results.
It can also inform more targeted approaches as to which
gene to include in the study. Another unique aspect of
Neurocarta is the ability that users have to enter their own
annotations. This enables them to share unpublished
results with collaborators as well as put their findings in the
context of existing data and facilitate interpretation.
Investigating gene-to-phenotype associations for
neurodevelopmental disorders
We gathered positive associations from Neurocarta
(March 12, 2012). There were 14,983 unique gene-
phenotype associations, consisting of many-to-many
relationships between 4,560 genes and 1,555 phenotypes
(Disease Ontology terms only). We decided to focus our
analysis on neurodevelopmental disorders since we
performed in-depth annotations on them. We categorized
the genes based on which disease they were annotated for
(ASD, CP, or FASD) and defined them as being “specific”
if they were only associated with this one disease (Table 3).
We observed that ASD has the largest fraction of specific
Table 3 Genes in Neurocarta associated with
neurodevelopmental disorders






ASD 189 321 69.8
FASD 27 106 25.5
CP 23 124 22.1
ASD = Autism Spectrum Disorder; FASD = Fetal Alcohol Spectrum Disorder;
CP = Cerebral Palsy.
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might come from, we decided to investigate whether or
not biases might be present in the data. Previous work in
our lab [28] showed that genes associated with diseases
tend to be more “multifunctional” (i.e., they have more
Gene Ontology (GO) [29] annotations). Therefore, we
predicted that genes in Neurocarta would have a
multifunctionality bias, and that the genes associated with
multiple disorders would be even more multifunctional.
Indeed, we found that genes in Neurocarta tend to be
associated with a large number of GO annotations on
average (aggregate multifunctionality score = 0.8, where
1.0 is the highest possible bias and 0.5 would be no bias).
When we separated the genes specific to one disease
versus the rest, we confirmed our hypothesis that genes
associated with multiple disorders tend to be more multi-
functional than specific genes (Figure 4; Mann–Whitney
test, p-values: ASD = 2.6 × 10-15; FASD = 5.9 × 10 -3;Figure 4 Genes associated with multiple diseases in Neurocarta are mo
** P≤ 0.01; *** P≤ 0.001.CP = 7.8 × 10-2). In addition, our results suggested that
genes associated with FASD were more multifunctional
than those associated with ASD or CP. We hypothesized
that this might be due to the experimental approaches
used to study FASD. Indeed, 98% of the FASD studies in
Neurocarta are targeted (i.e., they use a candidate gene
approach) against only 55% for ASD and 72% for CP,
respectively. The multifunctionality bias in FASD candidate
genes might thus be due to researchers choosing
well-characterized genes for their studies rather than
the genome-wide approaches mostly used in ASD research
represented in the database. This might also explain the
fact that, in Neurocarta, ASD has the largest fraction of
specific genes, as mentioned above.
Comparison to similar existing resources
Several genotype to phenotype databases have been
created with the idea of aggregating data from several
sources in a common standardized online tool [1]. Some
of existing tools rely entirely on OMIM annotations and
only provide a more sophisticated portal to access data
[29-31]. Others automatically aggregate data from a
collection of resources, including OMIM, but they either
focus only on human annotations [32], or on only one
major phenotype database for a selection of model
organisms [33]. Finally, some of the tools have been
designed for human genetic association studies only and
aggregate data from automatic or curated review of there multifunctional than specific genes. Mann–Whitney test: * P≤ 0.1;
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various initiatives in that it aggregates data from different
organisms (human and animal models of diseases) and
different kinds of studies (from genetic association to basic
molecular experiments). It puts side-by-side data automat-
ically extracted from public resources as well as manually
curated from selected papers in the literature. All data goes
through a review process where only the most reliable
annotations are kept to reduce noise in the system. Finally,
Neurocarta is the only publicly-available online tool that
allows users to enter their own genotype to phenotype
associations, share them with other users, and analyze
them in the context of all existing annotations.
Future development
We are planning several lines of improvements to
Neurocarta’s data and software layers. Neurocarta currently
includes very few data from genome-wide association
studies because of the high rate of false positives that can
arise from these data. We have included data from
PDGene, AlzGene, and MSGene but only the top results
that reached significance in their meta-analyses of the data.
In the case of ADHDgene, we have decided to incorporate
their Hot Gene list even though it was only based on the
number of studies a gene was identified in. We are
currently investigating different options to incorporate the
most significant results from additional genetic association
data from public resources such as GAD [35], GWASdb
[36], or the GWAS catalog [37]. Another development that
we feel will add value to Neurocarta is to incorporate
automated Gemma differential expression analysis results.
Neurocarta is part of Gemma but currently does not take a
full advantage of this integration. In Gemma, gene expres-
sion datasets comparing control vs. disease cases are tagged
and easily identifiable. We will apply differential expression
analysis to these datasets using stringent thresholds to
identify genes differentially expressed in specific diseases.
We will then incorporate this analysis result as a new type
of evidence linking genes to phenotypes in Neurocarta.
Finally, a challenge in making the best use of the data is
that different sources have different levels of evidence
quality associated with them. For example, human
geneticists would generally rate evidence from animal
models as weak. Neurocarta does not directly capture
such distinctions, so we are in the process of devising
an evidence-rating scheme that will be used to auto-
matically rank genes with respect to their strength of
evidence in association with each disorder.
Conclusions
Neurocarta is a new online resource linking genes to
phenotypes. It brings together data from a wide variety
of public resources and from manual curation of the
literature. It is unique in that it allows users to entertheir own annotations and keep them private if they
wish to. In-depth annotations of genes involved in brain
development disorders are available but Neurocarta is
not restricted to a single disease. Instead, Neurocarta
enables users to visualize all diseases their gene of interest
might be associated with. This allows users not only to
extract candidate gene lists from the system, but also to
identify which of these genes are the most specific to their
disorder of interest and to quickly find papers supporting
these associations. Our analysis of the data in the context
of neurodevelopmental disorders demonstrates that existing
annotations linking genes to phenotypes are skewed to
genes that are well known and involved in many biological
functions. Neurocarta exposes this problem and makes
it easier for researchers to focus their attention on more
“specific” genes.
Availability and requirements
Neurocarta is publicly available at http://neurocarta.chibi.
ubc.ca.
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